A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: West China Hospital of Sichuan University, Wuhan Union Hospital, Huazhong University of Science and Technology, Hunan Cancer Hospital, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Fujian Medical University, First Affiliated Hospital of Fujian Medical University, Chongqing University, Chongqing Cancer Hospital, Antengene Corporation Limited (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410812232